Market Pulse LIVECAST Terminal Brief Politics Macro Calendar

More

Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Market Pulse LIVECAST

Menu

Home Market Pulse LIVECAST Terminal Brief Politics Macro Calendar Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Live News REGULATION L impact Jul 13, 2026, 01:08 PM UTC

BioMarin announces FDA accepts sNDA for full approval of Voxzogo

BioMarin Pharmaceutical...

SquawkNews Newsroom

BioMarin Pharmaceutical...

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

BMRN

Related stories

BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia BioMarin Pharmaceutical (BMRN) said Monday that the US Food and Drug Administration has accepted its supplemental new drug application seeking full approval of Voxzogo to treat chi L impact | REGULATION | Jul 13, 2026, 01:37 PM UTC Iperionx Insider Bought Shares Worth $497,228, According to a Recent SEC Filing Anastasios Arima, Director, Chief Executive Officer, on July 10, 2026, executed a purchase for 138,720 shares in Iperionx (IPX) for $497,228. Following the Form 4 filing with the S L impact | REGULATION | Jul 13, 2026, 01:12 PM UTC Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disord L impact | REGULATION | Jul 13, 2026, 01:04 PM UTC Iperionx Insider Bought Shares Worth $1,881,165, According to a Recent SEC Filing Todd Hannigan, Director and Executive Chairman, on July 10, 2026, executed a purchase for 525,000 shares in Iperionx (IPX) for $1,881,165. Following the Form 4 filing with the SEC, L impact | REGULATION | Jul 13, 2026, 12:31 PM UTC Enlivex Therapeutics receives RMAT designation for Allocetra from FDA Enlivex announced that... L impact | REGULATION | Jul 13, 2026, 12:23 PM UTC Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02 Armata Pharmaceuticals (ARMP) said Monday it has reached agreement with the US Food and Drug Administration on an agreed initial pediatric study plan for AP-SA02, clearing a regula L impact | REGULATION | Jul 13, 2026, 11:47 AM UTC

SQUAWK/NEWS

Real-time financial news agency. Market-moving headlines, macro, politics, filings and audio squawk built for traders.

Product

LiveCast
Terminal
Brief
Macro
Calendar
Search

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact

© 2026 SquawkNews robots / sitemap SquawkNews publishes factual market information and context. It is not investment advice and does not provide trade recommendations.